ImmuneFX Gene Therapy Could Be a Game-Changer for Cancer Treatment

UF startup and UF Innovate | Sid Martin Biotech alumni company Morphogenesis, Inc., a clinical-stage company that develops novel cell and gene therapies based out of Tampa, recently got FDA approval to expand human clinical trials with an innovative cancer vaccine. Grit Daily interviewed Morphogenesis CEO Dr. Patricia Lawman to get more information about this technology that could potentially be a game-changer in regard to cancer treatment. ImmuneFx is currently being studied in advanced Merkel Cell Carcinoma (MCC) and cutaneous Squamous Cell Carcinoma (cSCC) patients.